Adelmidrol

Description: Adelmidrol is a diethanolamide derivative of azelaic acid that exerts potent anti-inflammatory effects that are partly dependent on PPARgamma. Adelmidrol reduces NF-kappaB translocation, and COX-2 expression. In a murine experimental model of colitis induced by intracolonic administration of dinitrobenzene sulfonic acid, treatment with adelmidrol decreased diarrhea, body weight loss, and myeloperoxidase activity. Moreover, adelmidrol treatment reduced nuclear factor-kappaB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase expression; proinflammatory cytokine release; and the incidence of nitrotyrosine and poly(ADP)ribose in the colon. It also decreased the upregulation of ICAM-1 and P-selectin. Adelmidrol treatment produced a reduction of Bax and an intensification of Bcl-2 expression. In summary, adelmidrol exerts important anti-inflammatory effects that are partly dependent on PPARgamma, suggesting that this molecule may represent a new pharmacologic approach for inflammatory bowel disease treatment.

References: Mol Pharmacol. 2016 Nov; 90(5):549-561.